This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway. The target subjects are male or female, 18-70 years, diagnosed with MS according to revised McDonald criteria (9) with spasticity and pain associated with the spasticity. Spasticity is evaluated based on self-reported spasticity using the numerical rating scale (NRS) which describes the average score of spasticity over the last 24 hours at \>4 (where the scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst possible spasticity), - combined with pain in the lower extremities last 24 hours. The pilot investigation is done to evaluate if FlowOx2.0™ can be used to treat spasticity with concomitant pain in patients with multiple sclerosis, using intermittent negative pressure affecting arteriovenous reflex.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
Neuro-SysMed, Dept. of Neurology, Haukeland University Hospital, & Dept. of Clinical Medicine, University of Bergen
Bergen, Norway
RECRUITINGSelf-Reported Spasticity, using Numerical Rating Scale:
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx from baseline to week 4
Time frame: 4 weeks
Desire to continue treatment
Proportion of patients who wish to continue treatment with FlowOx beyond 4 weeks
Time frame: 4 weeks
Self-Reported Spasticity, using Numerical Rating Scale
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx compared to baseline
Time frame: 3 months, 6 months
Spasticity - modified Ashworth Scale
The unabbreviated scale title: Modified Ashworth Scale The minimum and maximum values: 0, 4 Higher scores mean a worse outcome. Change in spasticity measured by modified Ashworth scale from baseline to week 4, month 3 and month 6.
Time frame: 4 weeks, 3 months and 6 months
Self-reported pain using Numerical Rating Scale
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher score means worse pain. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx from baseline.
Time frame: 4 weeks, 3 months and 6 months
T25-FW
Change of Timed 25-Foot Walk (T25-FW) from baseline
Time frame: 4 weeks, 3 months, 6 months
Expanded Disability Status Scale
The unabbreviated scale title: Expanded Disability Status Scale The minimum and maximum values: 0, 10 Higher score means worse disability status. Change of functional score measured by Expanded Disability Status Scale (EDSS) and compared to baseline
Time frame: 4 weeks, 3 months, 6 months
Self-reported sleep (NRS)
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher score means worse sleep. Change in self reported sleep quality will measured by (NRS) and compared to baseline
Time frame: 4 weeks, 3 months, 6 months
Hospital Anxiety and Depression Scale
The unabbreviated scale title: Hospital Anxiety and Depression Scale The minimum and maximum values: 0, 3 Higher score means worse outcome. The Scale has 14 questions, the scores will be summarized at each time point and compared to baseline
Time frame: 4 weeks, 3 months, 6 months
Fatigue Scale for Motor and Cognitive Functions
The unabbreviated scale title: Fatigue Scale for Motor and Cognitive Functions (FSMC) The FSMC is an assessment of MS-related cognitive and motor fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue). Two subscales (mental and physical fatigue) can be made. Items included in the subscale mental are 1-4-7-8-11-13-15-17-18-20 and items included in the subscale physical are 2-3-5-6-9-10-12-14-16-19. Changes in the scores will be compared to baseline.
Time frame: 4 weeks, 3 months, 6 months
Multiple Sclerosis Impact Scale (MSIS-29)
The unabbreviated scale title: Multiple Sclerosis Impact Scale The minimum and maximum values: 1, 5 Higher score means worse condition. There are 29 questions, change in reported status will be compared to baseline
Time frame: 4 weeks, 3 months, 6 months
SDMT
Change in cognition measured by the Symbol Digit Modalities Test (SDMT) The Symbol Digit Modalities Test (SDMT) is a cognitive task. It consists of a sheet of paper with, at the top, a sequence of nine symbols and nine corresponding numbers (key). The task sequence consists of a series of symbols, each with a blank space underneath. Within a 90-second time limit the subject is required, consulting the key as necessary, to insert the numbers associated with the symbols. Changes in the performance will be compared to baseline.
Time frame: 4 weeks, 3 months, 6 months
Change in medication
Medication used by the patients at the start of the trial will be recorded. Any change in frequency of use or dose of the medication to treat spasticity an/or pain will be recorded and compared to baseline.
Time frame: 4 weeks, 3 months and 6 monhts
Compliance
"Compliance" / use of FlowOx, is automatically logged in the machine and will be read after 4 weeks
Time frame: 4 weeks, 3 months, 6 months
Safety- Incidence of device related adverse and serious adverse events
The number and type of adverse events and servere device related events during the study will be recorded. To evaluate safety of FlowOx by assessment of device deficiencies and adverse events, non-serious and serious, rated for causality
Time frame: 4 weeks, 3 months, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.